{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:22:29Z","timestamp":1788844949526,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100466","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T11:46:18Z","timestamp":1632743178000},"page":"100466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage"],"prefix":"10.1016","volume":"29","author":[{"given":"Jeffrey","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki A.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100466_bib0001","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100466_bib0002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0003","first-page":"19","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours","volume":"17","author":"Khan","year":"2008","journal-title":"Eur. J. Cancer. Care. (Engl)."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0004","first-page":"7","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim","volume":"26","author":"Dale","year":"2018","journal-title":"Support. Care Cancer."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ctarc.2021.100466_bib0006","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0007","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","article-title":"Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor","volume":"29","author":"Arvedson","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.ctarc.2021.100466_bib0008","unstructured":"Amgen Inc., 2021. Neulasta (pegfilgrastim) prescribing information. [cited 2021 August 3] Available from: https:\/\/www.pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/neulasta\/neulasta_pi_hcp_english.pdf."},{"key":"10.1016\/j.ctarc.2021.100466_bib0009","unstructured":"Amgen Inc., 2021. Neupogen (filgrastim) prescribing information. [cited 2021 August 3] Available from: https:\/\/www.pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/neupogen\/neupogen_pi_hcp_english.pdf."},{"issue":"28","key":"10.1016\/j.ctarc.2021.100466_bib0010","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100466_bib0011","unstructured":"National Comprehensive Cancer Network\u00ae, 2021. NCCN\u00ae Clinical Practice Guidelines in oncology: Hematopoietic Growth factors, Version 4.2021. [cited 2021 August 3] Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"10.1016\/j.ctarc.2021.100466_bib0012","unstructured":"American Society of Clinical Oncology, 2021. Cancer treatment & supportive care. [cited 2021 August 3] Available from: https:\/\/www.asco.org\/asco-coronavirus-resources\/care-individuals-cancer-during-covid-19\/cancer-treatment-supportive-care."},{"key":"10.1016\/j.ctarc.2021.100466_bib0013","first-page":"1","article-title":"Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic","author":"Griffiths","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw"},{"issue":"30","key":"10.1016\/j.ctarc.2021.100466_bib0014","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100466_bib0015","unstructured":"National Comprehensive Cancer Network\u00ae, 2020. NCCN\u00ae Clinical Practice Guidelines in oncology: Acute Myeloid leukemia, Version 3.2021. [cited 2021 August 3] Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"key":"10.1016\/j.ctarc.2021.100466_bib0016","unstructured":"National Comprehensive Cancer Network\u00ae, 2021. NCCN\u00ae Clinical Practice Guidelines in oncology: Myelodysplastic syndromes, Version 3.2021. [cited 2021 August 3] Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf."},{"issue":"12","key":"10.1016\/j.ctarc.2021.100466_bib0017","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/phar.1150","article-title":"Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor","volume":"32","author":"Bradley","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100466_bib0018","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk. Lymphoma."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100466_bib0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ajem.2006.10.005","article-title":"Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma","volume":"25","author":"Watring","year":"2007","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ctarc.2021.100466_bib0020","article-title":"Spontaneous splenic rupture in a patient with small-cell lung cancer","author":"Rodrigues Fernandes","year":"2013","journal-title":"BMJ Case. Rep. 2013"},{"key":"10.1016\/j.ctarc.2021.100466_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222561","article-title":"Spontaneous splenic rupture as a rare complication of G-CSF injection","author":"Benguerfi","year":"2018","journal-title":"BMJ Case. Rep. 2018"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-015-3590-1","article-title":"Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer","volume":"154","author":"Calip","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100466_bib0024","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2021.100466_bib0025","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/1078155218799859","article-title":"Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level","volume":"25","author":"Baig","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100466_bib0026","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/1078155218792698","article-title":"Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia","volume":"25","author":"Zullo","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1078155214528551","article-title":"White blood cell growth factor use in an outpatient oncology clinic: lessons and opportunities learned","volume":"21","author":"Le","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100466_bib0028","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JOP.2012.000662","article-title":"Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic","volume":"9","author":"Waters","year":"2013","journal-title":"J. Oncol. Pract."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0029","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12788\/jcso.0117","article-title":"Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients","volume":"13","author":"Bernens","year":"2015","journal-title":"J. Community Support Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100466_bib0030","first-page":"2167","article-title":"Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma","volume":"22","author":"Langeberg","year":"2014","journal-title":"Support. Care Cancer."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0031","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/s12885-019-6010-9","article-title":"Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100466_bib0032","first-page":"439","article-title":"Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor","volume":"25","author":"Weycker","year":"2017","journal-title":"Support. Care Cancer."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100466_bib0033","first-page":"225","article-title":"Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer","volume":"7","author":"Schuman","year":"2009","journal-title":"J. Support. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0034","first-page":"6","article-title":"Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal malignancies","volume":"4","author":"Matera","year":"2021","journal-title":"Cancer Med. J."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100466_bib0035","first-page":"873","article-title":"A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI","volume":"27","author":"Eckstrom","year":"2019","journal-title":"Support. Care Cancer."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100466_bib0036","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1078155210384445","article-title":"Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim","volume":"17","author":"Covert","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100466_bib0037","first-page":"3889","article-title":"\u201cSame-day\u201d administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale","volume":"24","author":"Marion","year":"2016","journal-title":"Support. Care Cancer."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100466_bib0038","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","article-title":"Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment","volume":"35","author":"Weycker","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.ctarc.2021.100466_bib0039","first-page":"2309","article-title":"Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?","volume":"24","author":"Weycker","year":"2016","journal-title":"Support. Care Cancer."},{"issue":"12","key":"10.1016\/j.ctarc.2021.100466_bib0040","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","article-title":"Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015","volume":"33","author":"Weycker","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100466_bib0041","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","article-title":"Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged \u226565 years: a retrospective evaluation using Medicare claims","volume":"34","author":"Weycker","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/03007995.2010.536527","article-title":"Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study","volume":"27","author":"Tan","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.ctarc.2021.100466_bib0043","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/1060028017714554","article-title":"Safety and efficacy of pegfilgrastim when given less than 14 days before the next chemotherapy cycle: review of every 14-day chemotherapy regimen containing 5-FU continuous infusion","volume":"51","author":"Donkor","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100466_bib0044","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1188\/10.CJON.81-86","article-title":"Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting","volume":"14","author":"Flores","year":"2010","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"11","key":"10.1016\/j.ctarc.2021.100466_bib0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/annonc\/mdw309","article-title":"Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)","volume":"27","author":"Aapro","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100466_bib0046","first-page":"1819","article-title":"Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study","volume":"25","author":"Bokemeyer","year":"2017","journal-title":"Support. Care Cancer."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100466_bib0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jval.2014.01.002","article-title":"Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors","volume":"17","author":"Johnson","year":"2014","journal-title":"Value Health"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:21:49Z","timestamp":1762842109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":47,"alternative-id":["S2468294221001623"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100466","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100466"}}